

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

**HIGH-CONCENTRATION HYDROXOCOBALAMIN HYDROCHLORIDE
INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA (MMA)**

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that high-concentration hydroxocobalamin hydrochloride injection (the “**Product**”) developed by the Group has obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China for the treatment of methylmalonic acidemia (“**MMA**”).

MMA is an autosomal recessive disorder of organic acid metabolism that may manifest as early as in the neonatal period and has already been included in the First List of Rare Diseases jointly formulated by five departments, including the National Health Commission, in China. Hydroxocobalamin injection is the first-line recommendation for the treatment of vitamin B12-responsive MMA, and lifelong use is required. Currently, no hydroxocobalamin injection targeting the indication of MMA has been approved for marketing either domestically or internationally, and there remains an urgent unmet medical need for patients with MMA.

The indication for this clinical approval is methylmalonic acidemia with elevated homocysteine level (cbl C type) in children. The Product has become the first hydroxocobalamin injection approved in China for clinical trials in MMA and its development is expected to offer a new treatment option for patients with MMA, providing a promising clinical development value.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 3 July 2025

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.